‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
Introductions and Objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the treatment of hepatitis C is historically challenging. The purpose of the current study was t...
Guardado en:
Autores principales: | Fabrizio Fabrizi, Cristina Alonso, Ana Palazzo, Margarita Anders, Maria Virginia Reggiardo, Hugo Cheinquer, Maria Grazia Videla Zuain, Sebastian Figueroa, Manuel Mendizabal, Marcelo Silva, Ezequiel Ridruejo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a10a721d539a4ef798649bedda9515fc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Possible acute rejection associated with the use of the new antihepatitis C virus medications
por: Khaled Ar Karkout, et al.
Publicado: (2019) -
An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
por: Fabrizio Fabrizi, et al.
Publicado: (2021) -
Trasplante combinado hepato-renal: a propósito de un caso
por: Roque E,Jorge, et al.
Publicado: (2003) -
Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
por: Ibrahim Anam Ezzelregal, et al.
Publicado: (2020) -
Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)